SYDNEY -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released an in-depth report, Bladder Cancer - Global Clinical Trial Landscape 2024, offering key insights for stakeholders across the oncology and clinical research sectors.

Bladder cancer remains a significant health challenge worldwide, with over 614,000 new cases and 220,600 deaths recorded in 2022. Novotech’s latest report provides a detailed examination of the evolving landscape in bladder cancer research, with a focus on clinical trial trends, emerging therapeutic strategies, and regional variations in patient outcomes.

Key Highlights from the Report:

· Bladder Cancer Statistics: A thorough analysis of incidence and survival data, highlighting that Europe and Asia account for the majority of global cases.
· Clinical Trial Landscape: An overview of over 1,500 bladder cancer clinical trials initiated since 2019, with North America, Asia-Pacific, and Europe leading in trial volume.
· Advancements in Treatment: Exploration of innovative therapies, including immunotherapy, targeted treatments, and combination therapies, which are opening new avenues in bladder cancer care.
· Future Projections: Bladder cancer cases are projected to exceed 1.2 million annually by 2050, underscoring the urgent need for advanced treatment options and accessible healthcare solutions.

This report explores valuable information for biotech professionals, oncologists, researchers and scientists. By examining trial density, recruitment efficiencies, and regional disparities in treatment outcomes, the report provides actionable insights for those aiming to enhance the efficiency and effectiveness of bladder cancer trials.